1. This case-control study found that in patients with atrial fibrillation concomitant Serotonin Reuptake Inhibitor (SSRI) and Oral Anticoagulants (OAC) was associated with an increased risk of major bleeding compared with OAC use alone. 2. This increased risk was highest in the first 30 days of continuous, concomitant use. Evidence Rating Level: 2 (Good) Antidepressants,
Concomitant Use of Selective Serotonin Reuptake Inhibitors With Oral Anticoagulants and Risk of Major Bleeding 1. This case-control study found that in patients with atrial fibrillation concomitant Serotonin Reuptake Inhibitor (SSRI) and Oral Anticoagulants (OAC) was associated with an increased risk of major bleeding compared with OAC use alone. 2. This increased risk was highest
Pharmacogenomics is gaining support in mental health and polypharmacy, where the data make a strong case for improvements in clinical and economic outcomes.
Some patients trying to quit anti-depressant drugs experience withdrawal effects that linger for months, even years. Newsweek spoke with a leading researcher about how to avoid them.